Abstract 1938P
Background
Magnitude of clinical benefit from drugs used in tumours must be evaluated using validated and reproducible tools. European Society for Medical Oncology-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS) and American Society for Medical Oncology (ASCO) Value Framework (ASCO-VF) are the most important. Here, we evaluate characteristics and outcomes of clinical trials supporting drugs used in STS and BS, and their association with ESMO-MCBS and ASCO-VF.
Methods
We reviewed publications between January 1988 and December 2022 that support the recommendations of NCCN guidelines version 1.2023 for STS and 3.2023 for BS (gastrointestinal stromal tumours were excluded). We collected data regarding trial characteristics, efficacy, toxicity and quality of life (QoL). ESMO-MCBS and ASCO-VF were applied. Substantial clinical benefit was defined as a grade 4 or 5 (in a scale from 1 to 5) for ESMO-MCBS and a ≥45 for ASCO-VF.
Results
We identified 119 studies (71 for STS and 48 for BS) that support the use of 49 drugs or combinations. ESMO-MCBS could be applied in 58 trials (48.7%). Of them, 37 (64%) were single arm and 21 (36%) randomized clinical trials (RCT; 13 phase III and 8 phase II). ASCO-VF could only be applied in 10 of the previously described (6 phase III and 4 phase II RCT). QoL was reported in 17.2% (10/58), all published beyond 2011. Among these, only 1 (10%) showed improvement in QoL. Only 33.3% of RCT (7/21) demonstrated improvement in overall survival. Ten (17.2%) trials, all of them RCT, met the ESMO-MCBS substantial benefit threshold (7 involving STS and 3 BS). Only 4 of these met the ASCO-VF criteria (all for STS). Spearman’s correlation coefficient between scales was 0.65.
Conclusions
Less than half of the studies supporting the NCCN recommendations for the prescription of drugs in advanced sarcomas can be evaluated using validated scales to assess the magnitude of their clinical benefit. Substantial clinical benefit was only achieved in a minority of those. QoL analysis should be incorporated in further studies to better evaluate their actual clinical benefit. Correlation among ESMO-MCBS and ASCO-VF was noteworthy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1940P - Deep molecular profiling of advanced synovial sarcoma as a basis for interventional clinical trials
Presenter: Richard Schlenk
Session: Poster session 15
1941P - Preliminary efficacy and safety of SHR-2554 in advanced epithelioid sarcoma: A phase II trial
Presenter: Haiyan Hu
Session: Poster session 15
1942P - Non-metastatic malignant phyllodes tumors of the breast (B-MPT): A retrospective analysis from a referral center
Presenter: Carmine Valenza
Session: Poster session 15
1944P - MAGE-A4 and NY-ESO-1 expression analysed in a synovial sarcoma tissue micro-array
Presenter: Lore De Cock
Session: Poster session 15
1945P - Diagnostic and therapeutic impact of liquid biopsy in soft tissue sarcomas: A case series
Presenter: Tarek Assi
Session: Poster session 15
1946P - Bladder primary sarcomas (BSar): A genomic landscape and clinical outcomes study
Presenter: ALINA BASNET
Session: Poster session 15
1947P - Predictors and outcomes of recurrent retroperitoneal liposarcoma: New insights into its recurrence patterns
Presenter: Huan Deng
Session: Poster session 15
1948P - Concordance of the pathological diagnosis between local institutional and central judgment in high-grade non-round-cell sarcomas: A supplementary analysis of JCOG1306
Presenter: Eisuke Kobayashi
Session: Poster session 15
1949P - Pegylated liposomal doxorubicin (PLD) combined with trabectedin as a treatment option in uterine sarcomas
Presenter: Laura Strobel
Session: Poster session 15